Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Single-Dose PF-04965842 on QTc Interval in Healthy Volunteers
NCT03386279Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of abrocitinib in atopic dermatitis (AD) (6 arms), sponsored by Pfizer. Primary endpoint: Relationship between QTc change and PF-04965842 concentration at 24 hours. Started Jul 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03386279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386279.